-
1
-
-
0035857351
-
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy
-
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285: 785-95.
-
(2001)
JAMA
, vol.285
, pp. 785-795
-
-
-
2
-
-
27744461726
-
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
-
DOI 10.1096/fj.05-4221fje
-
Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19:1842-4. (Pubitemid 41598769)
-
(2005)
FASEB Journal
, vol.19
, Issue.13
, pp. 1842-1844
-
-
Poole, K.E.S.1
Van Bezooijen, R.L.2
Loveridge, N.3
Hamersma, H.4
Papapoulos, S.E.5
Lowik, C.W.6
Reeve, J.7
-
3
-
-
33845927993
-
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation
-
DOI 10.1359/jbmr.061002
-
van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22:19-28. (Pubitemid 46032593)
-
(2007)
Journal of Bone and Mineral Research
, vol.22
, Issue.1
, pp. 19-28
-
-
Van Bezooijen, R.L.1
Svensson, J.P.2
Eefting, D.3
Visser, A.4
Van Der, H.G.5
Karperien, M.6
Quax, P.H.A.7
Vrieling, H.8
Papapoulos, S.E.9
Ten, D.P.10
Lowik, W.G.M.C.11
-
4
-
-
78650646959
-
Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways
-
Krause C, Korchynskyi O, de Rooij K, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010;285:41614-26.
-
(2010)
J Biol Chem
, vol.285
, pp. 41614-41626
-
-
Krause, C.1
Korchynskyi, O.2
De Rooij, K.3
-
5
-
-
34250823973
-
Minireview: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton
-
DOI 10.1210/en.2007-0270
-
Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-43. (Pubitemid 46984775)
-
(2007)
Endocrinology
, vol.148
, Issue.6
, pp. 2635-2643
-
-
Baron, R.1
Rawadi, G.2
-
6
-
-
0035282968
-
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
-
Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10:537-43. (Pubitemid 32184286)
-
(2001)
Human Molecular Genetics
, vol.10
, Issue.5
, pp. 537-543
-
-
Balemans, W.1
Ebeling, M.2
Patel, N.3
Van Hul, E.4
Olson, P.5
Dioszegi, M.6
Lacza, C.7
Wuyts, W.8
Van Den, E.J.9
Willems, P.10
Paes-Alves, A.F.11
Hill, S.12
Bueno, M.13
Ramos, F.J.14
Tacconi, P.15
Dikkers, F.G.16
Stratakis, C.17
Lindpaintner, K.18
Vickery, B.19
Foernzler, D.20
Van Hul, W.21
more..
-
7
-
-
22244474640
-
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
-
DOI 10.1101/gr.3437105
-
Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005;15: 928-35. (Pubitemid 40994212)
-
(2005)
Genome Research
, vol.15
, Issue.7
, pp. 928-935
-
-
Loots, G.G.1
Kneissel, M.2
Keller, H.3
Baptist, M.4
Chang, J.5
Collette, N.M.6
Ovcharenko, D.7
Plajzer-Frick, I.8
Rubin, E.M.9
-
8
-
-
44449099165
-
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
-
DOI 10.1359/jbmr.080216
-
Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23:860-9. (Pubitemid 351768804)
-
(2008)
Journal of Bone and Mineral Research
, vol.23
, Issue.6
, pp. 860-869
-
-
Li, X.1
Ominsky, M.S.2
Niu, Q.-T.3
Sun, N.4
Daugherty, B.5
D'Agostin, D.6
Kurahara, C.7
Gao, Y.8
Cao, J.9
Gong, J.10
Asuncion, F.11
Barrero, M.12
Warmington, K.13
Dwyer, D.14
Stolina, M.15
Morony, S.16
Sarosi, I.17
Kostenuik, P.J.18
Lacey, D.L.19
Simonet, W.S.20
Hua, Z.K.21
Paszty, C.22
more..
-
9
-
-
65549152230
-
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of post-menopausal osteoporosis
-
Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of post-menopausal osteoporosis. J Bone Miner Res 2009;24:578-88.
-
(2009)
J Bone Miner Res
, vol.24
, pp. 578-588
-
-
Li, X.1
Ominsky, M.S.2
Warmington, K.S.3
-
10
-
-
77953481395
-
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength
-
Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25: 948-59.
-
(2010)
J Bone Miner Res
, vol.25
, pp. 948-959
-
-
Ominsky, M.S.1
Vlasseros, F.2
Jolette, J.3
-
11
-
-
84868290353
-
Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases
-
Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012;33:747-83.
-
(2012)
Endocr Rev
, vol.33
, pp. 747-783
-
-
Ke, H.Z.1
Richards, W.G.2
Li, X.3
Ominsky, M.S.4
-
12
-
-
84873558051
-
WNT signaling in bone homeostasis and disease: From human mutations to treatments
-
Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013;19:179-92.
-
(2013)
Nat Med
, vol.19
, pp. 179-192
-
-
Baron, R.1
Kneissel, M.2
-
13
-
-
78650958526
-
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
-
Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
-
(2011)
J Bone Miner Res
, vol.26
, pp. 19-26
-
-
Padhi, D.1
Jang, G.2
Stouch, B.3
Fang, L.4
Posvar, E.5
-
14
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
-
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
-
(1999)
Annals of Internal Medicine
, vol.130
, Issue.6
, pp. 461-470
-
-
Levey, A.S.1
Bosch, J.P.2
Lewis, J.B.3
Greene, T.4
Rogers, N.5
Roth, D.6
-
15
-
-
28744432803
-
Bone mineral density in sclerosteosis; affected individuals and gene carriers
-
DOI 10.1210/jc.2005-1235
-
Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis: affected individuals and gene carriers. J Clin Endocrinol Metab 2005;90:6392-5. (Pubitemid 41759290)
-
(2005)
Journal of Clinical Endocrinology and Metabolism
, vol.90
, Issue.12
, pp. 6392-6395
-
-
Gardner, J.C.1
Van Bezooijen, R.L.2
Mervis, B.3
Hamdy, N.A.T.4
Lowik, C.W.G.M.5
Hamersma, H.6
Beighton, P.7
Papapoulos, S.E.8
-
16
-
-
81855180504
-
Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover
-
van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011;26:2804-11.
-
(2011)
J Bone Miner Res
, vol.26
, pp. 2804-2811
-
-
Van Lierop, A.H.1
Hamdy, N.A.2
Hamersma, H.3
|